{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:45:19Z","timestamp":1789231519796,"version":"build-2803163510"},"reference-count":29,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"MIUR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Sodium glucose co-transporter-2 inhibitors exert clinically relevant cardiorenal protection. Among several mechanisms, inhibition of sodium-hydrogen exchanger-3 (NHE3) in proximal renal tubules has been proposed in rodents. Demonstration of this mechanism with the associated electrolyte and metabolic changes in humans is lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The present proof-of-concept study was designed to explore the involvement of NHE3 in modulating the response to sodium glucose co-transporter-2 inhibitors in humans.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty healthy male volunteers received 2 tablets of empagliflozin 25 mg during a standardized hydration scheme; freshly voided urines and blood samples were collected at timed intervals for 8 hours. Protein expression of relevant transporters was examined in exfoliated tubular cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Urine pH levels increased after empagliflozin (from 5.81 \u00b1 0.5 to 6.16 \u00b1 0.6 at 6 hours, P = .008) as did urinary output (from median, 1.7; interquartile range [IQR, 0.6; 2.5] to 2.5 [IQR, 1.7; 3.5] mL\/min\u22121, P = .008) and glucose (from median, 0.03 [IQR, 0.02; 0.04] to 34.8 [IQR, 31.6; 40.2] %, P &amp;lt; .0001), and sodium fractional excretion rates (from median, 0.48 [IQR, 0.34; 0.65] to 0.71 [IQR, 0.55; 0.85] %, P = .0001), whereas plasma glucose and insulin concentrations decreased and plasma and urinary ketones increased. Nonsignificant changes in NHE3, phosphorylated NHE3, and membrane-associated protein 17 protein expression were detected in urinary exfoliated tubular cells. In a time-control study in 6 participants, neither urine pH nor plasma and urinary parameters changed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In healthy young volunteers, empagliflozin acutely increases urinary pH while inducing a substrate shift toward lipid utilization and ketogenesis, without significant changes in renal NHE3 protein expression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad088","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T07:52:09Z","timestamp":1676533929000},"page":"e567-e573","source":"Crossref","is-referenced-by-count":14,"title":["Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects"],"prefix":"10.1210","volume":"108","author":[{"given":"Edoardo","family":"Biancalana","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa , Pisa I-56126 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa , Pisa I-56126 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raggi","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa , Pisa I-56126 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Distaso","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa , Pisa I-56126 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Tric\u00f2","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa , Pisa I-56126 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Baldi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa , Pisa I-56126 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-1584","authenticated-orcid":false,"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[{"name":"Consiglio Nazionale delle Ricerche (CNR) Institute of Clinical Physiology , Pisa I-56126 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7855-8253","authenticated-orcid":false,"given":"Anna","family":"Solini","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa , Pisa I-56126 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"issue":"4","key":"2023071417191245500_dgad088-B1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.ackd.2021.02.006","article-title":"Sodium-glucose cotransporter 2 inhibition: rationale and mechanisms for kidney and cardiovascular protection in people with and without diabetes","volume":"28","author":"Pollock","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"15","key":"2023071417191245500_dgad088-B2","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.3390\/ijms22157976","article-title":"Cardioprotection by SGLT2 inhibitors-does it all comes down to Na+?","volume":"22","author":"Trum","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023071417191245500_dgad088-B3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.yjmcc.2012.11.019","article-title":"Structural and functional insights into the cardiac Na+\/H+ exchanger","volume":"61","author":"Lee","year":"2013","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"2023071417191245500_dgad088-B4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00125-007-0628-x","article-title":"Enhanced activity of the myocardial Na+\/H+ exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: critical role of Akt","volume":"50","author":"Darmellah","year":"2007","journal-title":"Diabetologia"},{"issue":"3","key":"2023071417191245500_dgad088-B5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"2023071417191245500_dgad088-B6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"issue":"3","key":"2023071417191245500_dgad088-B7","doi-asserted-by":"crossref","first-page":"C348","DOI":"10.1152\/ajpcell.00115.2012","article-title":"Regulation of the human Na+-dependent glucose cotransporter hSGLT2","volume":"303","author":"Ghezzi","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"issue":"11","key":"2023071417191245500_dgad088-B8","doi-asserted-by":"crossref","first-page":"C1569","DOI":"10.1152\/ajpcell.00017.2012","article-title":"Deciphering the mechanisms of the Na+\/H+ exchanger-3 regulation in organ dysfunction","volume":"302","author":"Girardi","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"2023071417191245500_dgad088-B9","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl 1","key":"2023071417191245500_dgad088-B10","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjcard.2019.10.027","article-title":"Renal effects of sodium-glucose co-transporter inhibitors","volume":"124","author":"Thomson","year":"2019","journal-title":"Am J Cardiol"},{"issue":"9","key":"2023071417191245500_dgad088-B11","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2023071417191245500_dgad088-B12","doi-asserted-by":"crossref","first-page":"F653","DOI":"10.1152\/ajprenal.00143.2018","article-title":"Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat","volume":"315","author":"Masuda","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"13","key":"2023071417191245500_dgad088-B13","doi-asserted-by":"crossref","first-page":"e016173","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2023071417191245500_dgad088-B14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","article-title":"Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial","volume":"44","author":"Scholtes","year":"2021","journal-title":"Diabetes Care"},{"issue":"7","key":"2023071417191245500_dgad088-B15","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/jim-2017-000445","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes","volume":"65","author":"Yoshimoto","year":"2017","journal-title":"J Investig Med"},{"issue":"5","key":"2023071417191245500_dgad088-B16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int"},{"issue":"10","key":"2023071417191245500_dgad088-B17","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.clinthera.2016.09.001","article-title":"Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Heise","year":"2016","journal-title":"Clin Ther"},{"issue":"23","key":"2023071417191245500_dgad088-B18","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1042\/CS20201274","article-title":"SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: tubular effects of SGLT2 inhibition in type 2 diabetes","volume":"134","author":"van Bommel","year":"2020","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"2023071417191245500_dgad088-B19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1681\/ASN.2015111282","article-title":"MAP17 Is a necessary activator of renal Na+\/glucose cotransporter SGLT2","volume":"28","author":"Coady","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2023071417191245500_dgad088-B20","author":"Biancalana"},{"issue":"2","key":"2023071417191245500_dgad088-B21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2023071417191245500_dgad088-B22","doi-asserted-by":"crossref","first-page":"567796","DOI":"10.3389\/fphys.2020.567796","article-title":"The redox communication network as a regulator of metabolism","volume":"11","author":"Corkey","year":"2020","journal-title":"Front Physiol"},{"issue":"5","key":"2023071417191245500_dgad088-B23","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"1","key":"2023071417191245500_dgad088-B24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13098-015-0044-1","article-title":"Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation","volume":"7","author":"Nakamura","year":"2015","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"2023071417191245500_dgad088-B25","doi-asserted-by":"crossref","first-page":"F532","DOI":"10.1152\/ajprenal.00365.2001","article-title":"Insulin activates Na+\/H+ exchanger 3: biphasic response and glucocorticoid dependence","volume":"283","author":"Klisic","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"2023071417191245500_dgad088-B26","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1172\/JCI79552","article-title":"Restoration of Na+\/H+ exchanger NHE3-containing macrocoplexes ameliorates diabetes-associated fluid loss","volume":"125","author":"He","year":"2015","journal-title":"J Clin Invest"},{"issue":"6","key":"2023071417191245500_dgad088-B27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2021111515","article-title":"Empagliflozin changes urine supersaturation by decreasing pH and increasing citrate","volume":"33","author":"Harmacek","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2023071417191245500_dgad088-B28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jat\/31.8.486","article-title":"Urine pH: the effects of time and temperature after collection","volume":"31","author":"Cook","year":"2007","journal-title":"J Anal Toxicol"},{"issue":"12","key":"2023071417191245500_dgad088-B29","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad088\/49451094\/dgad088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/8\/e567\/50884575\/dgad088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/8\/e567\/50884575\/dgad088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T17:21:17Z","timestamp":1689355277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/8\/e567\/7041118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,2,16]]},"published-print":{"date-parts":[[2023,7,14]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad088","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,2,16]]}}}